Wyeth And Santaris To Collaborate On RNA Antagonists
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish biotech gets $7 million upfront, $10 million equity investment in Locked Nucleic Acid platform licensing agreement.
You may also be interested in...
Pfizer Expands Santaris Deal to Boost Presence in RNA-Targeted Drug Development
RNA-targeted medicines receive a boost from Pfizer's expansion of its strategic alliance with Danish firm Santaris
Pfizer Expands Santaris Deal to Boost Presence in RNA-Targeted Drug Development
RNA-targeted medicines receive a boost from Pfizer's expansion of its strategic alliance with Danish firm Santaris
Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals
"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth